Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
-Forty Seven Inc.'s CD47 antibody to be evaluated in combination with PD-L1 antibody with the aim of engaging both T-cell and macrophage components of the immune system against acute myeloid leukemia and bladder cancer-
MENLO PARK, Calif., Jan. 11, 2018 /PRNewswire/ -- Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable patient's immune systems to defeat their cancer, today announced an agreement with Genentech Inc., a member of the Roche Group., for Genentech to sponsor two clinical trials combining Forty Seven's CD47 antibody, Hu5F9-G4, with Genentech's PD-L1 antibody, atezolizumab (TECENTRIQ®), in patients with acute myeloid leukemia (AML) and with urothelial (bladder) cancer.
CD47 is an immune modulator molecule overexpressed on cancer cells that sends inhibitory signals to macrophages. Binding of Hu5F9-G4 to CD47 takes the brakes off macrophages enabling them to phagocytose, or swallow, tumor cells.
Craig Gibbs, Ph.D., M.B.A., Chief Business Officer at Forty Seven Inc. said, "There is a large unmet medical need for new therapies for AML and bladder cancer patients, particularly those who are elderly or have compromised organ function and are not able to withstand the side-effects of chemotherapy. We are excited to evaluate these novel combinations in collaboration with a global leader in oncology."
CD47 blockade as another immune checkpoint therapy for cancer. Robert H. Vonderheide, Nature Medicine 21, 1122, 2015.
TECENTRIQ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
About Hu5F9-G4 and Forty Seven Inc.
Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in five clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma. For a comprehensive list of all Hu5F9-G4 trials, please visit clinicaltrials.gov. Forty Seven is located at 1490 O'Brien Drive, Suite A, Menlo Park, CA 94025, U.S.A.
For journalist enquiries please contact Ryan Ferrell at email@example.com or phone (312) 506-5202.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at firstname.lastname@example.org or phone (212) 362-1200.
SOURCE Forty Seven Inc.